Evommune, Inc.
EVMN
Get informed when a big investor buys or sells
+ FollowMarket Cap$531.68M
Close$
$-24.35
273% downside
Current Fair Value
273% downsideOvervalued by 273% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $531.68 Million |
|---|---|
| Enterprise Value | $479.76 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.18 |
| Beta | 0.96 |
| Outstanding Shares | 36,135,644 |
Return
| Return on Equity | -34.10% |
|---|---|
| Return on Assets | -31.35% |
| Return on Invested Capital | -35.52% |
Valuation & Multiples
| P/E Ratio | -5.18 |
|---|---|
| PEG | -3.76 |
| Price to Sales | - |
| Price to Book Ratio | 2.01 |
| Enterprise Value to Revenue | 47.98 |
| Enterprise Value to EBIT | -4.75 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
$1.33 M
Average shareholder expectationNext Earnings Call
Expected Date
October 16, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 109.68%▲ 23.40% |
|---|---|
| Total Invested | $793.41M▲ 70.37% |
| Investors Holding | 84▲ 25.00% |
ESG Score
No data
About Evommune, Inc.
45 employees
CEO: Luis C. Pena Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic sponta...